Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMV1BTP)

Drug Name
ISIS-SOD1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Amyotrophic lateral sclerosis 8B60.0 Phase 1 [1]
Motor neurone disease 8B60 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMV1BTP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SOD1 messenger RNA (SOD1 mRNA) TTP9K3Q SODC_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
SOD1 messenger RNA (SOD1 mRNA) DTT SOD1 11.785 10.388 11.246 11.267
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Amyotrophic lateral sclerosis
ICD Disease Classification 8B60.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
SOD1 messenger RNA (SOD1 mRNA) DTT SOD1 2.51E-01 -0.49 -0.43
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
2 ClinicalTrials.gov (NCT01041222) Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations. U.S. National Institutes of Health.